NOTch Just a Bladder Control Problem  by Xu, Keli et al.
Cancer Cell
Previewssuggestion that ‘‘Vitamin D priming’’ may
be an important adjuvant in the treat-
ment of pancreatic cancer via enabling
chemotherapeutic response as a result
of stromal reprogramming. Ablation of
reactive stroma or complete inhibition
of reactive stroma formation has previ-
ously been suggested as a way to inhibit
cancer progression. However, recent
studies suggest that ablation of reactive
stroma may not be very effective in
treating pancreatic cancer (Amakye
et al., 2013; O¨zdemir et al., 2014; Rhim
et al., 2014). In addition, this ablation-
centric paradigm may neither be easily
attainable in patients nor the most natu-
ral way to modulate or resolve stromal
reactions. The important new paradigm
that evolves from the Sherman et al.
(2014) study is the perspective that a
reprogramming switch in the biology of452 Cancer Cell 26, October 13, 2014 ª2014reactive stroma may be a more effective
way to ensure efficient drug delivery
and inhibit chemotherapeutic resistance
mechanisms. Not only was this reprog-
ramming attainable, it was achieved by
activating a native VDR with an analog
ligand, a rather natural approach. These
seminal observations are truly paradigm
shifting and may change the way we
think about targeting the tumor microen-
vironment in order to influence cancer
progression.REFERENCES
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Human bladder cancers harbor deletions and point mutations in genes coding for Notch receptors and pro-
teins involved in Notch signaling. This leads to elevatedMAPK pathway activation, as direct Notch-mediated
transcription of MAPK phosphatase DUSP is lost. These bladder tumors, with impaired Notch signaling, also
show basal differentiation.Bladder cancer, a common tumor asso-
ciated with smoking, causes approxi-
mately 150,000 deaths worldwide each
year. The vast majority of these tumors
are derived from urothelium, a stratified
epithelial structure lining the urine-
exposed surface of the bladder. A num-
ber of distinct bladder tumor types have
been characterized, including papillary
urothelial carcinomas, which are usually
low-grade/localized lesions with excel-
lent prognosis, as well as carcinoma
in situ (CIS) and muscle-invasive urothe-
lial carcinomas. Squamous cell carci-
nomas (SCCs) also represent a signifi-
cant, but variable, fraction of bladdercancers. Indeed, SCCs typically repre-
sent less than 5% of total bladder cancer
cases; however, schistosomiasis infec-
tions or irritation and inflammation asso-
ciated with frequent catheter use can in-
crease the incidence of this disease.
Interestingly, two groups used lineage-
tracing in a BBN [N-butyl-N-(4-hydroxy-
butyl)nitrosamine]-induced mouse model
of bladder cancer to identify the cell of
origin for most bladder cancers (Shin
et al., 2014; Van Batavia et al., 2014).
For example, Van Batavia et al. found
that papillary tumors derive from inter-
mediate layer epithelial progenitor cells,
whereas flat aggressive lesions like CIS,muscle-invasive tumors, and SCC of
the bladder arise through transformation
of cytokeratin 5/p63-expressing cells in
the basal layer (Van Batavia et al.,
2014). Shin et al. showed that basal cells,
which also express Shh, are absolutely
required for CIS and invasive tumor for-
mation (Shin et al., 2014). Surprisingly,
muscle-invasive tumors form at the
expense of SCC in Trp53 heterozygous
mutant mice (Van Batavia et al., 2014).
Over the past several years, a
number of groups have reported on
efforts to define the mRNA andmicroRNA
gene expression profiles and pro-
teomic profiles as well as the mutations,
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Previewscopy-number changes, and chromatin
modifications associated with the devel-
opment of bladder cancer. The most
comprehensive study, from The Cancer
Genome Atlas (TCGA) Network, was pub-
lished in the spring of 2014 (Network,
2014). This analysis revealed four distinct
molecular subtypes, including papillary-
and basal/squamous-like tumors. Rela-
tively common mutations included a
number that activated phosphatidylinosi-
tol-3-kinase (42% of tumors) and RAS/
mitogen-activated protein kinase (MAPK)
pathways (45% of tumors). The TP53
and RB1 genes or pathways were also
targeted in many cases, as were chro-
matin regulatory genes.
As bladder cancer is primarily associ-
ated with smoking and has a heavy muta-
tional load, it can be difficult to identify
some of the regulatory pathways that are
targeted for mutation, especially those
that can be altered though mutation at
multiple levels. In this regard, the Klinakis
lab took a candidate approach to test
for mutations in Notch receptor genes,
genes coding for components of the
g-Secretase complex required for Notch
receptor activation, and MAML1, which
codes for a Notch-binding transcriptional
regulatory protein. In their paper pub-
lished in Nature Medicine, they report
on mutations in NOTCH1, NOTCH2,
NOTCH3,MAML1, and NCSTN (Rampias
et al., 2014). In total, Notch pathway mu-
tations were identified in 31 of 72 bladder
tumors analyzed. Most were in NOTCH1,
NOTCH2, or MAML1. Many of these
were obvious loss-of-function mutations,
including deletion or nonsense mutations
generating a premature stop codon.
NOTCH1 copy-number loss was seen in
almost half of the tumors; in many cases,
these were found in tumors where the
remaining NOTCH1 allele was mutant.
Also, some alleles were predicted to
generate dominant-negative NOTCH pro-
teins, which could inhibit signaling by all
Notch receptors.
Patients with Notch pathway mutations
showed reduced levels of Notch-target
gene expression, including HEY1, HES1,
and CDKN1A (p21). They also showed
reduced survival in comparison to all
other bladder cancer patients. Some of
these tumors had mutations in RTK/
RAS/MAPK pathway genes, and high
levels of MAPK activation were noted.
Surprisingly, MAPK activation correlatedmore with loss of Notch signaling than
with RAS pathway mutation. Indeed,
Notch directly induced transcription of
multiple DUSP MAPK phosphatase
genes, a phenomenon first described in
C. elegans (Berset et al., 2001). Thus,
loss-of-function mutations in the Notch
pathway caused high levels of activated
phospho-MAPK to accumulate as a result
of reduced DUSP expression.
Notch genes were first implicated in
cancer through the identification of gain-
of-function alleles coding for oncopro-
teins mimicking the fragment generated
in response to ligand-mediated activa-
tion. Indeed, most T cell acute lympho-
blastic leukemias have mutations in
Notch1 that enhance activation either by
destabilizing the heterodimeric complex
formed between Notch’s N- and C-termi-
nal fragments on the cell surface or by sta-
bilizing the Notch1 C-terminal fragment
generated in response to ligand-induced
g-secretase cleavage. Similar alleles
have been detected at a relatively low fre-
quency in a number of cancers. In 2003,
the Radtke and Dotto labs found that
Notch can also function as a tumor sup-
pressor in the skin (Nicolas et al., 2003).
This remarkable result established a
paradigm for Notch signaling as tumor
suppressor that has been confirmed in a
number of tissues, most notably in the
context of squamous cell lesions in the
head and neck, as well as in lungs (Brake-
nhoff, 2011). Indeed, these findings can
be understood in the context of genetic
analysis of mouse lens development/
homeostasis, whereby homozygous dele-
tion of Notch1 caused age-dependent
transdifferentiation to skin (Vauclair et al.,
2007). Thus, in some tissues, particularly
those exposed to the external environ-
ment, Notch signaling is required to sup-
press skin-like formation. Stated differ-
ently, Notch signaling is required to form
and sustain nonskin differentiation pro-
grams in cells on the surface of the body
or exposed to the environment through
the lumen of internal epithelial tubes
(as in the lungs or bladder). Interestingly,
many of these tissues form stratified
or pseudostratified epithelial structures
with a basal cytokeratin 5/p63-expressing
layer that also functions to maintain
homeostasis through self-renewal and
differentiation. In such a context,
Notch and p63 function antagonistically,
whereby Notch signaling is involved inCancer Cell 26differentiation toward a more luminal cell
fate (Buono et al., 2006; Nguyen et al.,
2006).
While Notch pathway mutations were
distributed across all four molecular sub-
types, signaling as determined by HES1
and CDKN1A expression levels was
lowest in basal/squamous-like bladder
tumors. For direct testing of the effect
of disrupting Notch signaling in the
bladder, two models were generated:
one involved doxycycline-mediated dis-
ruption of Nicastrin in R26rtTA;tetO-Cre;
Ncstnflox/flox conditional mutant mice,
and the other involved urothelial-specific
disruption of Nicastrin in UpkII-Cre-
eGFP;Ncstnflox/flox mice. In both cases,
cytokeratin 5/p63-expressing basal-like
bladder tumors formed with rapid ki-
netics. These tumors showed high-level
phospho-MAPK accumulation that was
blocked through ectopic expression of
activated Notch1ICD.
These findings on Notch as urothelial
tumor suppressor in the bladder, together
with many insights from comprehensive
analysis of the bladder cancer genome
and proteome, highlight the opportunity
for targeted therapeutics. Indeed, Ram-
pias et al. (2014) have shown the depen-
dence of Notch-disrupted tumors on
elevated MAPK signaling. Despite this,
many challenges remain. For example,
it will be important to determine the rela-
tionship between mutational disruption
of Notch signaling and specific patholog-
ical features in bladder cancer. One might
expect Notch-impaired tumors to be
SCCs. Indeed, a quick look at TCGA
Network pathology reports on bladder
cancers with loss-of-function mutations
in the Notch pathway reveals that some
show squamous differentiation (http://
www.cbioportal.org/public-portal/). This
is by no means universal, but a link to
more basal differentiation has been
made in patients and in mouse models
(Rampias et al., 2014), suggesting that
Notch plays an important role in pre-
venting self-renewal of basal stem cells.
Simple and quantitative tests must be
developed to identify alterations in Notch
pathway signaling, as well as in other
major pathways implicated in bladder
cancer. Finally, combination therapies
must be developed for each pathological
and molecular subtype, and these should
be based on knowledge of pathway
crosstalk and dependencies, as well, October 13, 2014 ª2014 Elsevier Inc. 453
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Previewsas on how differentiation of the tumor
subtype or lineage impacts therapeutic
vulnerability.
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